A leading Chinese vaccine developer has applied for authorization to bring its Covid-9 shot to the market,
seeking to get a jump on Western rivals as the race for a working inoculation against the virus enters the final stretch.
China National Biotec Group Co. has submitted an application to Chinese regulators,
reported state media Xinhua Finance on Wednesday,
citing parent company Sinopharm’s vice general manager Shi Shengyi.
The application likely includes interim data from the company’s Phase III human testing conducted
in the Middle East and South America.
Stocks related to Sinopharm Group, including its Hong Kong unit, surged on Wednesday after the news.
https://www.bloomberg.com/news/articles/2020-11-25/china-vaccine-maker-seeks-approval-for-public-use-of-covid-shot?srnd=premium-asia 
China Vaccine Maker Applies for Public Use of Covid Shot
seeking to get a jump on Western rivals as the race for a working inoculation against the virus enters the final stretch.
China National Biotec Group Co. has submitted an application to Chinese regulators,
reported state media Xinhua Finance on Wednesday,
citing parent company Sinopharm’s vice general manager Shi Shengyi.
The application likely includes interim data from the company’s Phase III human testing conducted
in the Middle East and South America.
Stocks related to Sinopharm Group, including its Hong Kong unit, surged on Wednesday after the news.
https://www.bloomberg.com/news/articles/2020-11-25/china-vaccine-maker-seeks-approval-for-public-use-of-covid-shot?srnd=premium-asia